NASDAQ:GOVXW GeoVax Labs (GOVXW) Stock Price, News & Analysis → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Free GOVXW Stock Alerts $0.05 0.00 (0.00%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$0.05▼$0.0550-Day Range$0.02▼$0.0552-Week Range$0.02▼$0.28Volume100 shsAverage Volume4,077 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get GeoVax Labs alerts: Email Address Ad InvestorPlaceThe Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.Go here now for this breaking story. About GeoVax Labs Stock (NASDAQ:GOVXW)GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Read More GOVXW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GOVXW Stock News HeadlinesApril 4, 2024 | finance.yahoo.comGeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 VaccineMarch 28, 2024 | finance.yahoo.comGeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine CongressApril 18, 2024 | InvestorPlace (Ad)The Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.February 13, 2024 | finance.yahoo.comGeoVax Announces Multiple Patent Issuances and AllowancesFebruary 6, 2024 | finance.yahoo.comGeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine BoosterJanuary 29, 2024 | finanznachrichten.deGeoVax, Inc.: GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid RequirementJanuary 29, 2024 | markets.businessinsider.comEQS-News: GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid RequirementJanuary 29, 2024 | finance.yahoo.comGeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid RequirementApril 18, 2024 | InvestorPlace (Ad)The Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.January 4, 2024 | finance.yahoo.comGeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer PatientsDecember 27, 2023 | finance.yahoo.comGeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024December 19, 2023 | finanznachrichten.deGeoVax, Inc.: GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and SmallpoxDecember 19, 2023 | finance.yahoo.comGeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and SmallpoxNovember 14, 2023 | finance.yahoo.comProgress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023November 8, 2023 | finance.yahoo.comGeoVax Reports Third Quarter 2023 Financial Results and Provides Business UpdateOctober 30, 2023 | finance.yahoo.comGeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 VaccineOctober 25, 2023 | finance.yahoo.comGeoVax to Participate in Upcoming November Investor and Industry EventsOctober 9, 2023 | finance.yahoo.comGeoVax Receives Notice of Allowance for Marburg Vaccine PatentOctober 5, 2023 | finance.yahoo.comGeoVax Receives Notice of Allowance for HIV Vaccine PatentSeptember 26, 2023 | finance.yahoo.comGeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine DevelopmentSeptember 20, 2023 | finance.yahoo.comGeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia ConferenceAugust 29, 2023 | finance.yahoo.comGeoVax to Present at the Emerging Growth Conference on September 6, 2023August 10, 2023 | finance.yahoo.comGeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic LeukemiaAugust 9, 2023 | finance.yahoo.comGeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate UpdateJuly 24, 2023 | marketwatch.comGeoVax Labs Shares Rise 8% After Patent for Ebola VaccineJuly 11, 2023 | finance.yahoo.comGOVX - GeoVax Labs, Inc.July 10, 2023 | finance.yahoo.comGeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer ConferenceSee More Headlines Receive GOVXW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:GOVXW CUSIPN/A CIK832489 Webwww.geovax.com Phone16783847220FaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$81,526.00 Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. David Alan Dodd (Age 74)Chairman, President & CEO Comp: $384.2kDr. Mark J. Newman Ph.D. (Age 69)Chief Scientific Officer Comp: $291.5kDr. Kelly T. McKee Jr. (Age 73)M.D., M.P.H., Chief Medical Officer Comp: $361.03kDr. Harriet Latham Robinson Ph.D. (Age 86)Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board Mr. Mark W. Reynolds CPA (Age 62)CFO & Corporate Secretary Comp: $348.2kJeffrey WelchHead of Process Development & Manufacturing OperationsDr. John W. Sharkey Ph.D. (Age 68)Vice President of Business Development More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors GOVXW Stock Analysis - Frequently Asked Questions How have GOVXW shares performed in 2024? GeoVax Labs' stock was trading at $0.03 at the start of the year. Since then, GOVXW stock has increased by 63.7% and is now trading at $0.0491. View the best growth stocks for 2024 here. How do I buy shares of GeoVax Labs? Shares of GOVXW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GOVXW) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIBiden replacement revealed?Paradigm PressThe “Perfect Storm” for GoldGold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeThe Next Nvidia?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.